Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.44 |
| ▸ | CA2 | P00918 | 14/20 | 0.44 |
| ▸ | CA12 | O43570 | 13/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100163 | 0.92 | CA1 (0.44) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100074 | 0.89 | PTGS2 (0.44) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100115 | 0.89 | PTGS2 (0.45) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100078 | 0.88 | PTGS2 (0.44) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100109 | 0.88 | PTGS2 (0.44) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100196 | 0.87 | PTGS2 (0.46) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100190 | 0.87 | PTGS2 (0.42) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100104 | 0.87 | PTGS2 (0.45) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100086 | 0.87 | PTGS2 (0.43) | CA1CA2CA12PTGS2CA4 | |
| SCHEMBL13100173 | 0.86 | PTGS2 (0.41) | CA1CA2CA12PTGS2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | CA1 7/4885CA2 1/4885CA12 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.